Publications by authors named "Phillip Bourne"
Hydroxyurea (HU), a drug for treating cancers of the blood and the management of sickle cell anemia, induces hypogonadism in males. However, the impact of HU on testicular architecture and function, as well as its effects on the resumption of male fertility following treatment withdrawal, remain poorly understood. We used adult male mice to determine whether HU-induced hypogonadism is reversible.
View Article and Find Full Text PDFPerturbation of the developmental potential of preimplantation mouse embryos by hydroxyurea.
Int J Environ Res Public Health
May 2010
Women are advised not to attempt pregnancy while on hydroxyurea (HU) due to the teratogenic effects of this agent, based on results obtained from animal studies. Several case reports suggest that HU may have minimal or no teratogenic effects on the developing human fetus. Fourteen cases of HU therapy in pregnant patients diagnosed with acute or chronic myelogenous leukemia, primary thrombocythemia, or sickle cell disease (SCD) have been reported.
View Article and Find Full Text PDFArticle Synopsis
- - Two experiments examined whether male transgenic sickle cell mice exhibit reproductive issues similar to those in men with sickle cell disease, particularly looking for signs of hypogonadism and how hydroxyurea (HU) treatment affects this condition.
- - Blood samples and sperm quality metrics were analyzed from sickle cell mice and control mice, revealing that sickle cell mice had significantly lower testosterone levels, testis weight, and sperm quality measures compared to controls, indicating they were experiencing hypogonadism.
- - In the second experiment, administering HU resulted in a significant decrease in testis weight and size over 28 and 56 days, highlighting that HU exacerbates reproductive issues in transgenic sickle cell mice.